OrbiMed’s Redhill Biopharma RDHL Stock Holding History

OrbiMed’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-55	Closed	-$303K	–	138
2018 Q4	$303K	Sell	55 -230	-81%	-$1.76M	0.01%	128
2018 Q3	$2.52M	Sell	285 -280	-50%	-$2.28M	0.03%	139
2018 Q2	$4.82M	Hold	565	–	–	0.06%	128
2018 Q1	$2.91M	Hold	565	–	–	0.04%	129
2017 Q4	$2.9M	Hold	565	–	–	0.04%	120
2017 Q3	$6.11M	Hold	565	–	–	0.06%	118
2017 Q2	$4.87M	Hold	565	–	–	0.05%	115
2017 Q1	$5.42M	Hold	565	–	–	0.06%	115
2016 Q4	$5.91M	Hold	565	–	–	0.08%	110
2016 Q3	$7.85M	Hold	565	–	–	0.09%	113
2016 Q2	$6.14M	Hold	565	–	–	0.06%	108
2016 Q1	$6.92M	Hold	565	–	–	0.07%	106
2015 Q4	$7.28M	Hold	565	–	–	0.07%	101
2015 Q3	$7.29M	Hold	565	–	–	0.07%	102
2015 Q2	$9.95M	Sell	565 -121	-18%	-$1.92M	0.08%	107
2015 Q1	$9.98M	Buy	686 +80	+13%	+$1.14M	0.09%	104
2014 Q4	$8.07M	Hold	606	–	–	0.08%	101
2014 Q3	$7.98M	Hold	606	–	–	0.08%	101
2014 Q2	$10.6M	Sell	606 -26	-4%	-$413K	0.12%	82
2014 Q1	$8.9M	Buy	+632	New	+$8.47M	0.11%	98

Other funds holding RDHL

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed's RDHL Position: Q1 2019 in Review

OrbiMed sold out of Redhill Biopharma (RDHL) in Q1 2019, closing a stake of 55 shares — an estimated $303K sold.

OrbiMed first reported a position in RDHL in Q1 2014 and held it in 20 quarters. The position peaked at $10.6M in Q2 2014. 34 funds tracked by Wall St. Rank hold RDHL as of Q1 2019.

OrbiMed reported no remaining Redhill Biopharma position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 55 Redhill Biopharma shares in Q1 2019, an estimated $303K.
OrbiMed first reported a position in Redhill Biopharma in Q1 2014 and held it in 20 quarters.
OrbiMed's Redhill Biopharma position peaked at $10.6M in Q2 2014.
34 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.